Results 151 to 160 of about 21,307 (209)

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study. [PDF]

Hum Vaccin Immunother
Villagomez-Martinez S, Kharit S, Galustyan A, Zambrano B, Singh Dhingra M, B'Chir S, Syrkina O, Lyabis O, Rehm C.   +8 more
europepmc   +1 more source

Tetanus Toxoid Vaccination Coverage and Associated Factors among Childbearing Women in Ethiopia: A Systematic Review and Meta-Analysis. [PDF]

Biomed Res Int, 2021
Nigussie J, Girma B, Molla A, Mareg M.
europepmc   +1 more source

Overuse of tetanus toxoid vaccine: a common but under-addressed issue in Nepal. [PDF]

Ann Med Surg (Lond)
Shrestha S, Aryal R, Yadav RS, Baidya S, Acharya S, Bhandari SS.   +5 more
europepmc   +1 more source

Investigation of Cysteine Modifications in Recombinant Protein Tetanus Toxoid Heavy Chain Fragment C. [PDF]

J Am Soc Mass Spectrom, 2021
Cai CX, Schneck NA, Cozine T, Ivleva VB, Ragheb D, Gollapudi D, Patel A, Barefoot N, Gowetski DB, Lei QP.   +9 more
europepmc   +1 more source

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age. [PDF]

Hum Vaccin Immunother, 2022
Marshall GS, Pelton SI, Robertson CA, Oster P.   +3 more
europepmc   +1 more source

Factors associated with tetanus toxoid vaccine utilization among reproductive-age women in Debre Markos town, Ethiopia, 2021: a cross-sectional study. [PDF]

Ther Adv Vaccines Immunother
Tamiru YD, Sendo EG, Deressa JT.
europepmc   +1 more source

A cell-based in vitro assay for testing of immunological integrity of Tetanus toxoid vaccine antigen. [PDF]

NPJ Vaccines, 2021
Ticha O, Klemm D, Moos L, Bekeredjian-Ding I.   +3 more
europepmc   +1 more source

Tetanus toxoid immunization to reduce mortality from neonatal tetanus [PDF]

International Journal of Epidemiology, 2010
BACKGROUND: Neonatal tetanus remains an important and preventable cause of neonatal mortality globally. Large reductions in neonatal tetanus deaths have been reported following major increases in the coverage of tetanus toxoid immunization, yet the level
Hannah Blencowe, Joy E Lawn, Martha H Roper   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Hypersensitivity to tetanus toxoid

Journal of Allergy and Clinical Immunology, 1973
Abstract A high incidence of cutaneous hypersensitivity reactions to tetanus toxoid, 63 per cent immediate, 32 per cent Arthus type, and 74 per cent delayed reactions, were found in 70 tetanus-immunized individuals who had no history of clinical hypersensitivity to tetanus toxoid.
M A, Facktor, R A, Bernstein, P, Fireman
openaire   +2 more sources

Tetanus Toxoid Boosters

JAMA: The Journal of the American Medical Association, 1978
To the Editor.— I would like to respond to the question regarding the Arthus phenomenon following immunization with diphtheria-pertussin-tetanus (DPT) in the QUESTIONS AND ANSWERS section (238:2307, 1977). As noted by Zack Haddad, MD, the incidence of the Arthus-type response diminished when the interval between tetanus toxoid boosters increased.
openaire   +2 more sources